{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jacobsen JM"],"funding":["Intramural NIH HHS","Novo Nordisk A/S","National Institute of Diabetes and Digestive and Kidney Diseases","National Institutes of Health"],"pagination":["114501"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11380917"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["43(8)"],"pubmed_abstract":["Evaluation of weight loss drugs is usually performed in diet-induced obese mice housed at ∼22°C. This is a cold stress that increases energy expenditure by ∼35% compared to thermoneutrality (∼30°C), which may overestimate drug-induced weight loss. We investigated five anti-obesity mechanisms that have been in clinical development, comparing weight loss in mice housed at 22°C vs. 30°C. Glucagon-like peptide-1 (GLP-1), human fibroblast growth factor 21 (hFGF21), and melanocortin-4 receptor (MC4R) agonist induced similar weight losses. Peptide YY elicited greater vehicle-subtracted weight loss at 30°C (7.2% vs. 1.4%), whereas growth differentiation factor 15 (GDF15) was more effective at 22°C (13% vs. 6%). Independent of ambient temperature, GLP-1 and hFGF21 prevented the reduction in metabol"],"journal":["Cell reports"],"pubmed_title":["Housing mice near vs. below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans."],"pmcid":["PMC11380917"],"funding_grant_id":["ZIA DK075062","ZIA DK075063"],"pubmed_authors":["Ostergaard S","Pedersen K","Petersen N","Torz L","Raun K","Jacobsen JM","Gerstenberg MK","Wulff BS","John LM","Christoffersen BO","Kuhre RE","Andersen B","Reitman ML"],"additional_accession":[]},"is_claimable":false,"name":"Housing mice near vs. below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans.","description":"Evaluation of weight loss drugs is usually performed in diet-induced obese mice housed at ∼22°C. This is a cold stress that increases energy expenditure by ∼35% compared to thermoneutrality (∼30°C), which may overestimate drug-induced weight loss. We investigated five anti-obesity mechanisms that have been in clinical development, comparing weight loss in mice housed at 22°C vs. 30°C. Glucagon-like peptide-1 (GLP-1), human fibroblast growth factor 21 (hFGF21), and melanocortin-4 receptor (MC4R) agonist induced similar weight losses. Peptide YY elicited greater vehicle-subtracted weight loss at 30°C (7.2% vs. 1.4%), whereas growth differentiation factor 15 (GDF15) was more effective at 22°C (13% vs. 6%). Independent of ambient temperature, GLP-1 and hFGF21 prevented the reduction in metabol","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-05-29T09:31:28.517Z","creation":"2025-04-04T00:29:11.01Z"},"accession":"S-EPMC11380917","cross_references":{"pubmed":["39067024"],"doi":["10.1016/j.celrep.2024.114501"]}}